These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 19294736)

  • 1. Epigenetic silencing in non-neoplastic epithelia identifies E-cadherin (CDH1) as a target for chemoprevention of lobular neoplasia.
    Zou D; Yoon HS; Perez D; Weeks RJ; Guilford P; Humar B
    J Pathol; 2009 Jun; 218(2):265-72. PubMed ID: 19294736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability.
    Sarrió D; Moreno-Bueno G; Hardisson D; Sánchez-Estévez C; Guo M; Herman JG; Gamallo C; Esteller M; Palacios J
    Int J Cancer; 2003 Aug; 106(2):208-15. PubMed ID: 12800196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. E-cadherin alterations in atypical lobular hyperplasia and lobular carcinoma in situ of the breast.
    Mastracci TL; Tjan S; Bane AL; O'Malley FP; Andrulis IL
    Mod Pathol; 2005 Jun; 18(6):741-51. PubMed ID: 15696125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis.
    Vos CB; Cleton-Jansen AM; Berx G; de Leeuw WJ; ter Haar NT; van Roy F; Cornelisse CJ; Peterse JL; van de Vijver MJ
    Br J Cancer; 1997; 76(9):1131-3. PubMed ID: 9365159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer.
    Caldeira JR; Prando EC; Quevedo FC; Neto FA; Rainho CA; Rogatto SR
    BMC Cancer; 2006 Mar; 6():48. PubMed ID: 16512896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased levels of active c-Src distinguish invasive from in situ lobular lesions.
    Zou D; Yoon HS; Anjomshoaa A; Perez D; Fukuzawa R; Guilford P; Humar B
    Breast Cancer Res; 2009; 11(4):R45. PubMed ID: 19583841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hsa-miR-375 is differentially expressed during breast lobular neoplasia and promotes loss of mammary acinar polarity.
    Giricz O; Reynolds PA; Ramnauth A; Liu C; Wang T; Stead L; Childs G; Rohan T; Shapiro N; Fineberg S; Kenny PA; Loudig O
    J Pathol; 2012 Jan; 226(1):108-19. PubMed ID: 21953071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast.
    Droufakou S; Deshmane V; Roylance R; Hanby A; Tomlinson I; Hart IR
    Int J Cancer; 2001 May; 92(3):404-8. PubMed ID: 11291078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights into E-Cadherin Impairment in
    Uchida S; Sugino T
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted capture massively parallel sequencing analysis of LCIS and invasive lobular cancer: Repertoire of somatic genetic alterations and clonal relationships.
    Sakr RA; Schizas M; Carniello JV; Ng CK; Piscuoglio S; Giri D; Andrade VP; De Brot M; Lim RS; Towers R; Weigelt B; Reis-Filho JS; King TA
    Mol Oncol; 2016 Feb; 10(2):360-70. PubMed ID: 26643573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cadherin-catenin complex dissociation in lobular neoplasia of the breast.
    Morrogh M; Andrade VP; Giri D; Sakr RA; Paik W; Qin LX; Arroyo CD; Brogi E; Morrow M; King TA
    Breast Cancer Res Treat; 2012 Apr; 132(2):641-52. PubMed ID: 22080244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline CDH1 mutations in bilateral lobular carcinoma in situ.
    Petridis C; Shinomiya I; Kohut K; Gorman P; Caneppele M; Shah V; Troy M; Pinder SE; Hanby A; Tomlinson I; Trembath RC; Roylance R; Simpson MA; Sawyer EJ
    Br J Cancer; 2014 Feb; 110(4):1053-7. PubMed ID: 24366306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDH1 methylation analysis in invasive lobular breast carcinomas with and without gene mutation.
    González-Martínez S; Kajabova VH; Pérez-Mies B; Carretero-Barrio I; Caniego-Casas T; Sarrió D; Moreno-Bueno G; Gión M; Perez-García J; Cortés J; Smolkova B; Palacios J
    Virchows Arch; 2024 Aug; 485(2):291-297. PubMed ID: 38713384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disparate E-cadherin mutations in LCIS and associated invasive breast carcinomas.
    Rieger-Christ KM; Pezza JA; Dugan JM; Braasch JW; Hughes KS; Summerhayes IC
    Mol Pathol; 2001 Apr; 54(2):91-7. PubMed ID: 11322170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of heterozygosity on chromosome 11q13 in lobular lesions of the breast using tissue microdissection and polymerase chain reaction.
    Nayar R; Zhuang Z; Merino MJ; Silverberg SG
    Hum Pathol; 1997 Mar; 28(3):277-82. PubMed ID: 9042790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is upregulation of BCL2 a determinant of tumor development driven by inactivation of CDH1/E-cadherin?
    Karch I; Schipper E; Christgen H; Kreipe H; Lehmann U; Christgen M
    PLoS One; 2013; 8(8):e73062. PubMed ID: 24023670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of E-cadherin down-regulation in oral cancer: CDH1 gene expression and epigenetic blockage.
    Pannone G; Santoro A; Feola A; Bufo P; Papagerakis P; Lo Muzio L; Staibano S; Ionna F; Longo F; Franco R; Aquino G; Contaldo M; De Maria S; Serpico R; De Rosa A; Rubini C; Papagerakis S; Giovane A; Tombolini V; Giordano A; Caraglia M; Di Domenico M
    Curr Cancer Drug Targets; 2014; 14(2):115-27. PubMed ID: 24274398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. E-Cadherin Mutational Landscape and Outcomes in Breast Invasive Lobular Carcinoma.
    Djerroudi L; Bendali A; Fuhrmann L; Benoist C; Pierron G; Masliah-Planchon J; Kieffer Y; Carton M; Tille JC; Cyrta J; Ramtohul T; Bonneau C; Caly M; Renault V; Bidard FC; Mechta-Grigoriou F; Vincent-Salomon A
    Mod Pathol; 2024 Oct; 37(10):100570. PubMed ID: 39025406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ.
    De Leeuw WJ; Berx G; Vos CB; Peterse JL; Van de Vijver MJ; Litvinov S; Van Roy F; Cornelisse CJ; Cleton-Jansen AM
    J Pathol; 1997 Dec; 183(4):404-11. PubMed ID: 9496256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. αE-catenin is a candidate tumor suppressor for the development of E-cadherin-expressing lobular-type breast cancer.
    de Groot JS; Ratze MA; van Amersfoort M; Eisemann T; Vlug EJ; Niklaas MT; Chin SF; Caldas C; van Diest PJ; Jonkers J; de Rooij J; Derksen PW
    J Pathol; 2018 Aug; 245(4):456-467. PubMed ID: 29774524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.